Singapore, Dec. 15 -- Quanterix Corporation, a US.-based biotechnology company specialising in ultrasensitive biomarker detection, and its clinical diagnostics brand Lucent Diagnostics, together withEmocogInc., a digital healthcare company based in Seoul, South Korea, have entered into an exclusive distribution agreement for the Korean market covering theSimoa(R) (Single Molecule Array) technology platform - including the ultra-sensitive HD-X immunoassay analyzer and blood-based Alzheimer's biomarker reagents.

This agreement marks the first introduction of theSimoa(R) platform into Korea as a formally authorized In Vitro Diagnostic (IVD) device rather than a Research Use Only (RUO) instrument,representingan important milestone in the dev...